Bio-Techne’s Growth Projections Amid Fiscal Challenges

Company Performance and Market Outlook

Bio-Techne has recently released its fourth-quarter results, showcasing a 1% year-over-year organic revenue growth even amidst a challenging fiscal year. Despite facing headwinds, the company’s key growth areas—proteomics, cell and gene therapy, spatial biology, and molecular diagnostics—have shown impressive performance. Notably, the ExoDx Prostate test reported over 20% organic revenue growth, highlighting its robust market demand. However, the company did face declines in sectors like biopharma and academia, and in regions such as North America, Europe, and China. The strategic addition of Dr. Judith Klimovsky to the Board of Directors signals a forward-thinking move, enhancing their leadership team.